The government and opposition parties agreed that the prescription trial begun on 1 January 2018, extended in 2021 and due to end in 2025, would become permanent from 2026. It keeps its focus on multiple sclerosis, spinal cord injury, cancer and chronic pain, with better guidance for doctors; the health ministry's evaluation had found no new evidence strengthening the medical case.[1]
Listed for context. No score change is recorded for Denmark here.
References
Checked. The date and the event were compared with a source that was read.